Filana Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.4%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.95next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly86.6MTarget: Sufficient to fund operations into 2027
Quarterly Net Loss Quarterly-10.3MTarget: Narrowing loss through disciplined expense management
Quarterly Research and Development (R&D) Expenses Quarterly4.5MTarget: Controlled spending post-Alzheimer's trial wind-down
Watch Items
- FDA Clinical Hold on Simufilam IND for TSC-related EpilepsyTrigger: Submission of additional preclinical data and protocol design modifications to the FDAAction: Formally respond to the FDA's December 2025 Clinical Hold Letter to initiate the 30-day review clock
- Litigation Reserve and Securities Class Action SettlementTrigger: Payment of the $31.25 million loss contingency related to the proposed securities class action settlementAction: Monitor cash outflows and final court approval of the settlement to assess remaining cash runway
Research as of 24 Jul 2026